A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma

NCT05390528 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Tumors
Lymphoma
Metastatic Tumors

Interventions

DRUG: HLX301

Sponsor

Shanghai Henlius Biotech